ulbi20180207_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
 

FORM 8-K

 
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 

February 8, 2018

(Date of Report)

 
 

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 
 

Delaware

000-20852

16-1387013

(State of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

2000 Technology Parkway, Newark, New York

14513

(Address of principal executive offices)

(Zip Code)

 

(315) 332-7100

(Registrant’s telephone number, including area code)

 
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company  [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [ ]

 

 



 

 

 

 

Item 2.02 Results of Operations and Financial Condition

 

NEWARK, N.Y. February 8, 2018 – Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.1 million on revenue of $22.5 million for the fourth quarter ended December 31, 2017 compared to operating income of $1.6 million on revenue of $21.6 million for the fourth quarter of 2016. For total year 2017, Ultralife produced operating income of $6.5 million on revenue of $85.5 million compared to operating income of $3.8 million on revenue of $82.5 million for 2016.

 

“We ended a year of growth and accomplishments with our highest quarterly revenue, operating profit and EPS in five years. Driven by a 32% increase in revenue from a broad range of government and defense customers, we delivered a 9.1% operating profit margin, up 150 basis points over last year’s fourth quarter, on total Company revenue growth of 4%,” said Michael D. Popielec, President and Chief Executive Officer. “Throughout 2017, we aggressively pursued exciting new revenue contributions from market and sales reach expansion, new product development and customer partnerships, while preparing to launch new products to serve emerging IoT demand. We achieved our stated goal of generating profitable growth for the year, increasing operating income by 72% on a 4% gain in revenue. As a result of the actions taken in 2017 to lay the foundation for new revenue contributions in 2018, we are starting the year with a higher backlog than last year. The combination of new revenue opportunities and continued disciplined execution of our business model places us in an excellent position to extend our track record of profitable growth.”

 

Revenue was $22.5 million, an increase of $.9 million, or 4%, compared to $21.6 million for the fourth quarter of 2016 reflecting higher government/defense sales for both business segments. Battery & Energy Products sales decreased 5% to $16.8 million compared to $17.6 million last year due primarily to timing differences in medical sales which caused commercial sales to come in below last year, not fully offset by a 25% increase in government/defense sales. Communications Systems sales grew 42% to $5.7 million compared to $4.0 million for the same period last year reflecting a 64% year-over-year increase in shipments of core products such as our 20-watt amplifiers, universal vehicle adaptors and power supplies, as well as a 25% increase in Vehicle Installed Power Enhanced Riflemen Appliqué (“VIPER”) revenues.

 

Gross profit was $6.9 million, or 30.5% of revenue, compared to $6.8 million, or 31.5% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 28.6% compared to 29.4% last year, and Communications Systems’ gross margin was 36.2% compared to 40.6% last year, primarily due to sales mix.

 

Operating expenses were $4.8 million compared to $5.2 million last year reflecting continued tight control over discretionary spending. Operating expenses were 21.4% of revenue compared to 23.9% of revenue for the year earlier period.

 

Operating income was $2.1 million compared to $1.6 million last year for an operating margin of 9.1% compared to 7.6% last year.

 

Net income was $3.8 million, which includes a one-time $1.9 million tax benefit, compared to net income of $1.7 million last year. Reported earnings per share for the fourth quarter of 2017 of $0.24 include $0.12 from our operating performance compared to $0.11 per share for the fourth quarter of 2016, plus $0.12 related to the tax benefit. Earnings per share for the full year of $0.49 include $0.37 per share from our 2017 operating performance compared to $0.23 for 2016.

 

Income tax net benefit was $1.7 million for the fourth quarter of 2017 compared to $0.1 million last year. As a result of the Tax Cuts and Jobs Act, a one-time, non-cash tax benefit of $1.9 million was recognized in the fourth quarter of 2017 upon the revaluation, at the newly enacted 21% Federal tax rate, of deferred tax liabilities relating to book-to-tax differences on goodwill and other intangible assets. There was no earnings impact for the revaluation of our domestic deferred tax assets, which include our net operating losses, as they continue to be fully reserved.

 

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed as incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

 

 

 

 

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

    

(a) Exhibits.

 

Exhibit  
Number Description
   

99.1

Press Release of Ultralife Corporation dated February 8, 2018

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: February 8, 2018

 

ULTRALIFE Corporation

     
     
 

By:

/s/ Philip A. Fain

   

Philip A. Fain

   

Chief Financial Officer and Treasurer

 

 

 

 

EXHIBIT INDEX

 

Exhibit  
Number Description
   

99.1

Press Release of Ultralife Corporation dated February 8, 2018

 

ex_104618.htm

 

Exhibit 99.1

 

 

Company Contact:   Investor Relations Contact:
Ultralife Corporation    LHA
Philip A. Fain   Jody Burfening
(315) 210-6110   (212) 838-3777
pfain@ulbi.com   jburfening@lhai.com

                                   

                                      

Ultralife Corporation Reports Fourth Quarter Results

 

NEWARK, N.Y. February 8, 2018 – Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.1 million on revenue of $22.5 million for the fourth quarter ended December 31, 2017 compared to operating income of $1.6 million on revenue of $21.6 million for the fourth quarter of 2016. For total year 2017, Ultralife produced operating income of $6.5 million on revenue of $85.5 million compared to operating income of $3.8 million on revenue of $82.5 million for 2016.

 

“We ended a year of growth and accomplishments with our highest quarterly revenue, operating profit and EPS in five years. Driven by a 32% increase in revenue from a broad range of government and defense customers, we delivered a 9.1% operating profit margin, up 150 basis points over last year’s fourth quarter, on total Company revenue growth of 4%,” said Michael D. Popielec, President and Chief Executive Officer. “Throughout 2017, we aggressively pursued exciting new revenue contributions from market and sales reach expansion, new product development and customer partnerships, while preparing to launch new products to serve emerging IoT demand. We achieved our stated goal of generating profitable growth for the year, increasing operating income by 72% on a 4% gain in revenue. As a result of the actions taken in 2017 to lay the foundation for new revenue contributions in 2018, we are starting the year with a higher backlog than last year. The combination of new revenue opportunities and continued disciplined execution of our business model places us in an excellent position to extend our track record of profitable growth.”

 

 

Fourth Quarter 2017 Financial Results

 

Revenue was $22.5 million, an increase of $.9 million, or 4%, compared to $21.6 million for the fourth quarter of 2016 reflecting higher government/defense sales for both business segments. Battery & Energy Products sales decreased 5% to $16.8 million compared to $17.6 million last year due primarily to timing differences in medical sales which caused commercial sales to come in below last year, not fully offset by a 25% increase in government/defense sales. Communications Systems sales grew 42% to $5.7 million compared to $4.0 million for the same period last year reflecting a 64% year-over-year increase in shipments of core products such as our 20-watt amplifiers, universal vehicle adaptors and power supplies, as well as a 25% increase in Vehicle Installed Power Enhanced Riflemen Appliqué (“VIPER”) revenues.

 

Gross profit was $6.9 million, or 30.5% of revenue, compared to $6.8 million, or 31.5% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 28.6% compared to 29.4% last year, and Communications Systems’ gross margin was 36.2% compared to 40.6% last year, primarily due to sales mix.

 

 

 

 

Operating expenses were $4.8 million compared to $5.2 million last year reflecting continued tight control over discretionary spending. Operating expenses were 21.4% of revenue compared to 23.9% of revenue for the year earlier period.

 

Operating income was $2.1 million compared to $1.6 million last year for an operating margin of 9.1% compared to 7.6% last year.

 

Net income was $3.8 million, which includes a one-time $1.9 million tax benefit, compared to net income of $1.7 million last year. Reported earnings per share for the fourth quarter of 2017 of $0.24 include $0.12 from our operating performance compared to $0.11 per share for the fourth quarter of 2016, plus $0.12 related to the tax benefit. Earnings per share for the full year of $0.49 include $0.37 per share from our 2017 operating performance compared to $0.23 for 2016.

 

Income tax net benefit was $1.7 million for the fourth quarter of 2017 compared to $0.1 million last year. As a result of the Tax Cuts and Jobs Act, a one-time, non-cash tax benefit of $1.9 million was recognized in the fourth quarter of 2017 upon the revaluation, at the newly enacted 21% Federal tax rate, of deferred tax liabilities relating to book-to-tax differences on goodwill and other intangible assets. There was no earnings impact for the revaluation of our domestic deferred tax assets, which include our net operating losses, as they continue to be fully reserved.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.

 

 

Conference Call Information

 

Ultralife will hold its fourth quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

(Unaudited)

 

   

December 31,

   

December 31,

 
   

2017

   

2016

 
ASSETS  

Current Assets:

               

Cash

  $ 18,330     $ 10,706  

Trade Accounts Receivable, Net

    14,657       13,179  

Inventories

    26,326       23,456  

Prepaid Expenses and Other Current Assets

    2,603       2,079  

Total Current Assets

    61,916       49,420  
                 

Property, Equipment and Improvements, Net

    7,570       7,999  

Goodwill, Intangibles and Other Assets

    27,700       27,325  

Total Assets

  $ 97,186     $ 84,744  
                 
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

 
                 

Current Liabilities:

               

Accounts Payable

  $ 8,787     $ 7,292  

Accrued Compensation and Related Benefits

    2,413       1,258  

Accrued Expenses and Other Current Liabilities

    3,039       2,778  

Total Current Liabilities

    14,239       11,328  

Deferred Income Taxes and Other Non-Current Liabilities

    3,898       5,556  

Total Liabilities

    18,137       16,884  
                 

Shareholders' Equity:

               

Common Stock

    1,966       1,932  

Capital in Excess of Par Value

    180,211       178,163  

Accumulated Deficit

    (82,894 )     (90,542 )

Accumulated Other Comprehensive Loss

    (1,611 )     (3,080 )

Treasury Stock

    (18,469 )     (18,443 )

Total Ultralife Equity

    79,203       68,030  

Non-Controlling Interest

    (154 )     (170 )

Total Shareholders’ Equity

    79,049       67,860  
                 

Total Liabilities and Shareholders' Equity

  $ 97,186     $ 84,744  

 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

   

Three Month Periods Ended

   

Year Ended

 
   

December 31,

   

December 31,

   

December 31,

   

December 31,

 
   

2017

   

2016

   

2017

   

2016

 

Revenues:

                               

Battery & Energy Products

  $ 16,812     $ 17,611     $ 69,789     $ 64,753  

Communication Systems

    5,697       4,014       15,742       17,707  

Total Revenues

    22,509       21,625       85,531       82,460  
                                 

Cost of Products Sold:

                               

Battery & Energy Products

    12,011       12,436       50,130       45,173  

Communication Systems

    3,632       2,384       9,169       12,179  

Total Cost of Products Sold

    15,643       14,820       59,299       57,352  
                                 

Gross Profit

    6,866       6,805       26,232       25,108  
                                 

Operating Expenses:

                               

Research and Development

    1,059       1,508       4,737       5,946  

Selling, General and Administrative

    3,757       3,653       15,019       15,399  

Total Operating Expenses

    4,816       5,161       19,756       21,345  
                                 

Operating Income

    2,050       1,644       6,476       3,763  
                                 

Other Expense (Income)

    (19 )     16       181       183  

Income Before Income Taxes

    2,069       1,628       6,295       3,580  
                                 

Income Tax (Benefit) Provision

    (1,739 )     (115 )     (1,369 )     98  
                                 

Net Income

    3,808       1,743       7,664       3,482  
                                 

Net Income (Loss) Attributable to Non-Controlling Interest

    8       (2 )     16       (27 )
                                 

Net Income Attributable to Ultralife Corporation

  $ 3,800     $ 1,745     $ 7,648     $ 3,509  
                                 
                                 

Other Comprehensive Income:

                               

Foreign Currency Translation Adjustments

    716       (858 )     1,469       (2,173 )

Comprehensive Income Attributable to Ultralife

  $ 4,516     $ 887     $ 9,117     $ 1,336  
                                 
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Basic

  $ 0.24     $ 0.11     $ 0.49     $ 0.23  
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted

  $ 0.24     $ 0.11     $ 0.48     $ 0.23  
                                 

Weighted Average Shares Outstanding – Basic

    15,627       15,259       15,528       15,261  
                                 

Weighted Average Shares Outstanding – Diluted

    16,031       15,360       15,858       15,405